Loading…
Employees: 5,379
Size Jiangsu Kanion Pharmaceutical (600557.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 2203rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.73 on 6 Nov 2026.
Performance Over six months the shares fell 5.6%, against -16.4% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 8.3% over the last twelve months (peer median +7.4%); the operating margin is 7.4% (peer median 5.3%).
Valuation It trades at 21.0× forward earnings against a peer median of 21.9× (7th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points above its cost of capital (6.6% WACC).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.37B | CN¥3.27B | CN¥3.86B | CN¥4.81B | CN¥4.28B |
| Revenue growth | — | -15% | -20% | +12% | — |
| Gross profit | CN¥2.58B | CN¥2.28B | CN¥2.72B | CN¥3.46B | CN¥2.99B |
| EBITDA | n/a | CN¥448M | CN¥497M | CN¥610M | CN¥592M |
| Net income | CN¥316M | CN¥304M | CN¥392M | CN¥464M | CN¥434M |
| Free cash flow | CN¥15.8M | CN¥99.1M | CN¥248M | CN¥676M | CN¥789M |
| Capital expenditure | CN¥603M | CN¥522M | CN¥477M | CN¥311M | CN¥211M |
| Total debt | CN¥33.1M | CN¥407M | CN¥548M | CN¥471M | CN¥11.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600557.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.2% | -3.7% | 5th highest of 21 |
| 6-month return | -5.6% | -16.4% | 4th highest of 20 |
| Distance from 52-week high | -23.4% | -35.7% | 6th highest of 21 |
| Revenue growth (TTM) | +8.3% | +7.4% | 9th highest of 19 |
| Operating margin | 7.4% | 5.3% | 9th highest of 19 |
| Forward P/E | 21.0× | 21.9× | 7th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 3.4% | 5.3% | 6th least demanding of 13 |
| Growth delivered (Del g) | +1.8% | +5.6% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +1.6 pp | +1.4 pp | 6th most demanding of 13 |
| ROIC minus cost of capital | +2.5 pp | -1.1 pp | 6th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |